The purpose of this study is to test an experimental drug called RMC-6236. RMC-6236 is an experimental drug, which means that it is not approved by the United States (US) Food and Drug Administration (FDA) or any other health authorities. RMC-6236 is currently being investigated in other ongoing studies in non-small cell lung cancer (NSCLC). If you consent and meet the study requirements, you will be randomly assigned to receive either RMC-6236 or docetaxel.

In this study, we want to see if a new drug called Ziftomenib can help treat or cure Leukemia. We want to find out if it is safe and if it works well for people with this disease.

To determine if neoadjuvant immunotherapy combined with response-adapted oncologic surgery improves site-reported event-free survival (EFS) compared to standard-of-care surgery in resectable stage III/IV cutaneous squamous cell carcinoma (CSCC)

We're trying to find out if a special gel is safe and easy for people with cervical cancer to use. This is for those who are also getting chemotherapy and radiation. We want to see if the gel does its job well, is quick to use, and helps keep healthy tissues safe.

Help us test a new health information website designed to give rural communities relevant information about prostate cancer. Use the tool, share your thoughts, and help improve health resources for your community.

The purpose is to evaluate if the sonrotoclax in combination with obinutuzumab or rituximab works better and is safe in participants compared to venetoclax plus rituximab for patients with this diagnosis.

The purpose of this immunotherapy study is to compare two different chemotherapy treatments administered before breast cancer surgery to see which has the better outcome.

Do you have a blood cancer or have received a stem cell transplant and have been diagnosed with a respiratory infection? If so, you might be eligible to take part in a study to see if an experimental treatment is effective at reducing the severity of the respiratory infection.

An important goal of this study is to evaluate the length of time cancer is not growing or spreading in participants when treated with zanzalintinib compared to everolimus. In addition, this study will also evaluate if zanzalintinib can shrink tumors and help participants live longer as compared to everolimus. This information will help researchers learn if zanzalintinib can be used to treat neuroendocrine cancer.

Do you have Acute Myeloid Leukemia (AML) and want to try a new study drug that might help treat your cancer?